Activity Restriction
BehavioralRecommendation to restrict physical activity in pregnant women with a short cervix. This may include increased rest or bed rest according to local clinical practice.
Other names: Bed Rest, AR
NCT Number: NCT07577388
Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.
The use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.
The overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).
The primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.
Secondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.
Through the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.
The primary outcome is gestational age in days (continuous).
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Pregnant women with gestational age 20+0 to 33+6
Recommendation to restrict physical activity in pregnant women with a short cervix. This may include increased rest or bed rest according to local clinical practice.
Other names: Bed Rest, AR
Recommendation to continue normal daily activity in pregnant women with a short cervix, without restricting physical activity.
Other names: Activity, No Bed Rest, NAR
Time frame: At birth (from inclusion until delivery)
Gestational age at birth measured in completed days of pregnancy. This is calculated based on the estimated due date from ultrasound (crown-rump lenght <14weeks).
Time frame: At birth
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: From inclusion to 42 days after delivery
Admission to an intensive care unit or a unit providing 24-hour medical supervision, mechanical ventilation, or continuous vasoactive drug support at any time during pregnancy and postpartum due to pregnancy- or childbirth-related complications
Time frame: At birth (from inclusion until delivery)
Time frame: From inclusion to 8 weeks after due date
Time frame: At inclusion and after 4 and 8 weeks.
Time frame: 12 months after stopped breastfeeding
Time frame: At birth (from inclusion until delivery)
Step count Time in supine position
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: At birth (from inclusion until delivery)
Time frame: From inclusion until discharge or 44 postmenstrual weeks
Time frame: From inclusion until discharge or 44 postmenstrual weeks
Intraventricular haemorrhage grade III or IV, Periventricular leukomalacia
Time frame: From inclusion until discharge or 44 postmenstrual weeks
Necrotizing enterocolitis (NEC) requiring surgery (Bell's stage 3), Spontaneous intestinal perfo-ration (SIP) requiring surgical treatment
Time frame: From inclusion until discharge or 44 postmenstrual weeks
Mechanical ventilation or non-invasive ventilation (NIV)
Time frame: From inclusion until discharge or 44 postmenstrual weeks
Time frame: From inclusion to 5 days after birth
Definition: >5 days of i.v. antibiotics where the treatment starts within the first week after delivery.
Time frame: At birth (from inclusion until delivery)
Contact information is provided by the study sponsor or research team.
Julie Glavind
Other
BEWISE - Bed Rest With a Short Cervix on Preterm Birth
Acronym: BEWISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05114096
Complication of Prematurity, Female Urogenital Diseases and Pregnancy Complications
Calgary, Alberta, Canada
View Trial DetailsNCT06915428
Abortion, Habitual, Abortion, Spontaneous
Chapel Hill, North Carolina, United States
View Trial DetailsNCT04494529
Complication of Prematurity, Female Urogenital Diseases and Pregnancy Complications
Hamilton, Ontario, Canada
View Trial DetailsNCT03154177
Death, Female Urogenital Diseases and Pregnancy Complications
Kigali, Rwanda
View Trial Details